GlassScriptPhysician profile
Thomas R Vanderheyden
NPI 1528222387
$10,088.71
in general payments reported to CMS, 2019-2025
37 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $829 · 2021: $1,651 · 2022: $1,396 · 2023: $1,550 · 2024: $1,831 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,943 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.40 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,232.74 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Gilead Sciences, INC. | $1,409.52 | 2019-2025 | |
| Janssen Biotech, INC. | $1,056.01 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,024.71 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $709.65 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $356.82 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $261.88 | 2019-2024 | Dificid, Zerbaxa |
| Pfizer INC. | $239.13 | 2019-2025 | |
| Genzyme Corporation | $205.87 | 2022-2024 | |
| Allergan, INC. | $146.19 | 2019 | |
| Braintree Laboratories, INC. | $143.06 | 2020-2023 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $140.06 | 2020-2024 | Linzess |
| Amgen INC. | $112.81 | 2020-2025 | |
| Madrigal Pharmaceuticals | $111.24 | 2024-2025 | Resmetirom, Rezdiffra |
| Nestle Healthcare Nutrition INC. | $92.91 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $86.82 | 2019-2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $85.80 | 2023-2025 | Dupixent |
| Shionogi INC | $82.55 | 2019 | |
| Ferring Pharmaceuticals INC. | $77.46 | 2019-2022 | |
| Lilly USA, LLC | $75.74 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $68.83 | 2024-2025 | |
| Boston Scientific Corporation | $54.32 | 2020-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.92 | 2023-2024 | Cyltezo |
| Ucb, INC. | $44.68 | 2019 | |
| Dova Pharmaceuticals | $21.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.46 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $19.17 | 2020 | |
| Daiichi Sankyo INC. | $17.65 | 2021 | |
| Sirtex Medical INC | $17.35 | 2025 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $16.81 | 2025 | Iqirvo |
| Amag Pharmaceuticals, INC. | $16.67 | 2020 | |
| Shire North American Group INC | $16.30 | 2019 | |
| Qol Medical, LLC | $16.23 | 2023 | Sucraid |
| Endo Pharmaceuticals INC. | $14.94 | 2020 | |
| Alfasigma USA, INC. | $14.81 | 2020 | |
| Novo Nordisk INC | $14.73 | 2025 | Wegovy |
| Organon LLC | $10.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vanderheyden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.